. The primary and secondary outcomes after 6 and 12 months of treatment CONCLUSIONS: The results suggest that low dose CS (monthly pulses þ iv CYC) is non-inferior to conventional treatment (with oral CS and CYC) for adult with primary GN.
SP188 URINARY SOLUBLE CD163 AS AN ACTIVITY BIOMARKER IN
INCIDENT PATIENTS WITH ANCA-ASSOCIATED RENAL VASCULITIS.
Javier Villacorta The aim of this study was to analyze the behaviour of urinary sCD163 during the follow-up of newly diagnosed ANCA-vasculitis patients with renal involvement METHODS: Soluble CD163 was analyzed in six incident patients with biopsy-proven renal vasculitis between January and June 2016. Urinary sCD163 levels were mesured at the onset of the disease, and also at one and three months after immune suppressive therapy was iniciated. RESULTS: Partients were predominantly women (80%) and the mean age was 71,5 6 4 years. ANCA serology was positive and showed activity against MPO in all cases. Mean serum creatinine at diagnosis was 2,5 6 1,5 mg/dl. All patients were treated with steroids and immunsosupressants and achieved complete or partial remission after therapy. Urinary sCD163 was elevated at the onset of the disease in all cases. Mean sCD163 levels at the onset were 1,93 6 1,1. All patients experienced an early reduction of urinary sCD163 by one month (mean levels at 1 month were 0,13 6 0,09) At 3 months, three patients showed a reduction in urinary sCD163 higher of 50% of the initial value, whereas sCD163 levels were indetectable in the remaining cases. Urinary sCD163 levels did not correlate with neither ANCA titres nor other inflammatory markers. CONCLUSIONS: Urinary sCD163 is an excellent and stable biomarker for clinical use in patients with renal vasculitis. Elevated urinary SCD163 levels correlated with active renal flare of ANCA vasculitis, whereas deacraese of the values was observed when remission was achieved To the best of our knowledge, no case of combined anti-GBM disease and AAV during pregnancy has been described so far.
METHODS: RESULTS:
We describe a 30-year-old woman who presented with life-threatening pulmonary hemorrhage and an active urinary sediment with normal glomerular filtration rate in the 13 th week of pregnancy. Anti-GBM antibodies in serum were negative, but perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) were detected. A renal biopsy revealed necrotizing glomerulonephritis with linear IgG deposits along the glomerular basement membrane. A diagnosis of pulmonary renal syndrome caused by anti-GBM antibodies and p-ANCA (double-positive) was made. Plasma exchange was started but had to be changed to immunoadsorption because of an allergic reaction to fresh frozen plasma. Oral steroids (prednisolone 1 mg/kg body weight per day) were introduced. The patient also received one dose of intravenous cyclophosphamide (15 mg/kg body weight) followed by two 1g doses of rituximab. The patient responded quickly to treatment with resolution of pulmonary hemorrhage and urinary abnormalities. Her infant was delivered in the 38 th week of pregnancy by caesarian section. It was small for age but otherwise completely healthy. The B-cell count of the baby was normal. CONCLUSIONS: To our knowledge this is the first report of a double-positive pulmonary renal syndrome in pregnancy. This case illustrates that a renal biopsy during pregnancy may be valuable to establish a correct diagnosis. A therapeutic regimen consisting of immunoadsorption, steroids, cyclophosphamide and rituximab applied in the second trimester of pregnancy is highly effective and without detrimental side effects to mother and infant.
SP190 EXTRAMEMBRANOUS GLOMERULONEPHRITIS REVEALING RETROPERITONEAL LIPOSARCOMA
Cherine El Rifai 
INTRODUCTION AND AIMS:
Extramembranous glomerulonephritis is one of the most common causes of nephrotic syndrome in adults (about 20%). This glomerulopathy can occur during lupus, after taking medication, complicate cancer, or be secondary to hepatitis B, syphilis. But, most often, it is said to be idiopathic, in relation to the presence of autoantibodies, foremost among which is an antibody directed against a podocyte protein: the phospholipase A type M receptor (PLA2R). However, the discovery of these antibodies does not solve all the situations encountered, as illustrated by the existence of secondary extramembranous glomerulonephritis with anti-PLA2R activity.
METHODS:
We report a medical observation about a case RESULTS: In this spirit, we report the observation of a 64-year-old hypertensive patient admitted for the management of oedematous-ascitic syndrome. The investigations reveal an impure nephrotic syndrome with renal failure and microscopic hematuria. Renal biopsy shows immune complex deposits on the outer wall of the glomerular capillary wall. The diagnosis of extra-membranous gomerulonephritis is then made. No biomarker to predict the long-term prognosis of IMN is currently available. Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor-b superfamily and has been associated with chronic inflammatory disease. It has the potential to be a useful prognostic marker in patients with renal diseases, such as diabetic nephropathy and IgA nephropathy. This study examined whether GDF-15 is associated with the clinical parameters in IMN and showed that GDF-15 can predict IMN disease progression. METHODS: A total 35 patients with biopsy-proven IMN, treated at Chungnam National University Hospital from January 2010 to December 2015, were included. Patients younger than 18 years of age, those with secondary membranous nephropathy and those lost to follow-up before 12-months were excluded. Levels of GDF-15 at the time of biopsy were measured using enzyme-linked immunosorbent assays. Disease progression was defined as a 30% decline in estimated glomerular filtration rate (eGFR) or the development of end-stage renal disease. RESULTS: The mean follow-up was 44.1 months (range: 16-72 months). Using receiver operating curve analysis, the best serum GDF-15 cut-off value of for predicting Nephrology Dialysis Transplantation 
